Tendinitis Treatment Industry Market Share

Intended Audience

• Tendinitis Treatment Manufacturers


• Tendinitis Treatment Suppliers


• Medical Research Laboratories


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Potential Investors

Americas & Europe Tendinitis Treatment Market Segmentation

The Americas & Europe tendinitis treatment market is segmented on the basis of type, treatment, and end user.

On the basis of type, the market is segmented into Achilles tendinitis, supraspinatus tendinitis, tennis or golfer's elbow, De Quervain's tenosynovitis, and others.

On the basis of treatment, the market is segmented into diagnosis, therapy, shock wave therapy or surgery, medical devices, devices, and others.

Diagnosis is further segmented into physical examination, imaging tests, ultrasound, Magnetic Resonance Imaging (MRI) Scans, and others.

Therapy is further segmented into non-pharmacological and pharmacological therapy. Non-pharmacological therapy includes rest therapy, heat & cold therapy, occupational therapy, physical therapy, and others. Pharmacological therapy includes OTC drugs or pain relievers, corticosteroids injections, platelet-rich plasma (PRP), and others.

Medical devices segment is further segmented mechanical band, support tape, pre-cut strips, continuous rolls, and others.

On the basis of end user, the market is segmented into hospitals & clinics, medical research centers, academic institutes, and others.

Regional Analysis of the Americas & Europe Tendinitis Treatment Market   

America is the largest market for tendinitis treatment owing to an increasing demand for new treatment options for tendinitis, and rising prevalence of sport injuries and disease such as arthritis. Furthermore, increasing number of sport injuries also influence the growth of the market. Sports medicine, is now gaining roots in the developing, and the developed regions of America. In America, North America captures the largest share in the tendinitis treatment market. 

According to the Center for Disease Control and Prevention, an estimated 78 million i.e. 26% of the U.S. adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040. Additionally, the prevalence of tendinitis among athletes is found to be increasing from last few years in the U.S.

In Europe, the prevalence of diabetes and rheumatoid arthritis is on the rise. Furthermore, availability of funds for research and development activities in medical devices enhance the demand for technologically advanced devices for the diagnosis for tendinitis. Diabetes is one to the major risk factors for tendinitis. According to the report published by World Health Organization (WHO) in 2015, over 60 million people were suffering from diabetes in the European Region. Furthermore, lifestyle changes and lack of physical activity also influence the growth of this market in Europe. In Europe, Western European captures the largest share with German in leading position.

Recent Development

November 2023 

Camber Pharmaceuticals expands its product portfolio with the inclusion of Naproxen Oral Suspension, which is indicated for treating the signs and symptoms of tendinitis. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that works by reducing inflammation and pain.Hyloris Pharmaceuticals announces that it has received FDA approval for its new drug, HY01, for the treatment of chronic tendinitis. HY01 is a hyaluronic acid (HA) injection that works by lubricating and cushioning the tendons.Ortho Clinical Diagnostics announces that it has launched a new test, the Ortho Clinical Diagnostics Tendinitis Panel, which can be used to diagnose and monitor tendinitis. The test measures the levels of three proteins that are involved in the development of tendinitis.

October 2023 

A new study published in the journal Orthopaedics & Sports Physical Therapy finds that a combination of physical therapy and platelet-rich plasma (PRP) injections is effective in reducing pain and improving function in patients with tendinitis. PRP is a blood product that contains high concentrations of platelets, which are cells that play a role in healing.Another study published in the journal Pain Physician finds that a new type of corticosteroid injection, called triamcinolone acetonide microparticles (TA microparticles), is effective in reducing pain and improving function in patients with chronic tendinitis. TA microparticles are a long-acting form of corticosteroid that is released slowly over time.

September 2023 

The American Academy of Orthopaedic Surgeons (AAOS) releases a new clinical practice guideline for the management of tendinitis. The guideline recommends a combination of physical therapy, NSAIDs, and other treatments, such as corticosteroid injections or PRP injections, depending on the severity of the condition.The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awards a grant to a team of researchers at the University of California, San Francisco to develop a new type of stem cell therapy for tendinitis. The therapy involves injecting stem cells into the affected tendon to promote healing.

Key Findings:

• By type, Achilles tendinitis acquired the largest market share in 2016.


• By treatment, diagnosis accounted for the largest market share in 2016 and is valued at USD 1200 million.


• By end user, hospitals & clinics accounted for the largest market share of 41.8% in the Americas & Europe tendinitis market, in 2016.

Key Players in the Americas & Europe Tendinitis Treatment Market

Some of the key players in this market are: 

• Abbott (U.S.)


• Pfizer (U.S.)


• AstraZeneca (U.K)


• Bayer (Germany)


• Merck & Co. Inc. (Germany)


• GlaxoSmithKline plc (U.S.)


• Teva Pharmaceutical Industries (Israel)


• Boehringer Ingelheim Pharmaceuticals, Inc. (Germany)